JP2008519815A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008519815A5 JP2008519815A5 JP2007540716A JP2007540716A JP2008519815A5 JP 2008519815 A5 JP2008519815 A5 JP 2008519815A5 JP 2007540716 A JP2007540716 A JP 2007540716A JP 2007540716 A JP2007540716 A JP 2007540716A JP 2008519815 A5 JP2008519815 A5 JP 2008519815A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- use according
- alkenyl
- het
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 6
- 239000004475 Arginine Substances 0.000 claims 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 5
- 235000009697 arginine Nutrition 0.000 claims 5
- 125000004452 carbocyclyl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 3
- 101710085388 N(G),N(G)-dimethylarginine dimethylaminohydrolase Proteins 0.000 claims 2
- 102100035854 N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 Human genes 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- -1 hydroxy, amino Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- PSFAGQZQDBXGHP-ZETCQYMHSA-N (2s)-2-(cyclopropylamino)-5-(diaminomethylideneamino)pentanoic acid Chemical group NC(=N)NCCC[C@@H](C(O)=O)NC1CC1 PSFAGQZQDBXGHP-ZETCQYMHSA-N 0.000 claims 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 229930064664 L-arginine Natural products 0.000 claims 1
- 235000014852 L-arginine Nutrition 0.000 claims 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0425039A GB0425039D0 (en) | 2004-11-12 | 2004-11-12 | Chemical compounds |
| GB0425039.5 | 2004-11-12 | ||
| GB0510348.6 | 2005-05-20 | ||
| GB0510348A GB0510348D0 (en) | 2005-05-20 | 2005-05-20 | Chemical compounds |
| PCT/GB2005/004361 WO2006051314A2 (en) | 2004-11-12 | 2005-11-11 | Guanidine derivatives as inhibitors of ddah |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008519815A JP2008519815A (ja) | 2008-06-12 |
| JP2008519815A5 true JP2008519815A5 (enExample) | 2008-11-20 |
| JP5274838B2 JP5274838B2 (ja) | 2013-08-28 |
Family
ID=35908037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007540716A Expired - Lifetime JP5274838B2 (ja) | 2004-11-12 | 2005-11-11 | 化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8063104B2 (enExample) |
| EP (1) | EP1828109B1 (enExample) |
| JP (1) | JP5274838B2 (enExample) |
| AU (1) | AU2005303610B2 (enExample) |
| CA (1) | CA2587444C (enExample) |
| WO (1) | WO2006051314A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2587444C (en) | 2004-11-12 | 2013-09-10 | Ucl Business Plc | Guanidine derivatives as inhibitors of ddah |
| ES2430206T3 (es) * | 2006-10-03 | 2013-11-19 | Tekmira Pharmaceuticals Corporation | Formulación que contiene lípidos |
| DE102008061247A1 (de) * | 2008-12-10 | 2010-06-24 | Christian-Albrechts-Universität Zu Kiel | Inhibitoren der Dimethylarginin Dimethylaminohydrolase |
| WO2013123033A1 (en) * | 2012-02-14 | 2013-08-22 | The Board Of Trustees Of The Leland Stanford Junior University | Dimethylarginine dimethylaminohydrolase inhibitors and methods of use thereof |
| WO2014160947A1 (en) * | 2013-03-29 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Dimethylarginine dimethylaminohydrolase inhibitors and methods of use thereof |
| US10226418B2 (en) | 2014-05-12 | 2019-03-12 | Susie Q, Ltd. | Arginine-containing topical composition |
| US10792266B2 (en) | 2017-10-23 | 2020-10-06 | Epitracker, Inc. | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome |
| JP2021525249A (ja) | 2018-05-23 | 2021-09-24 | エピトラッカー インコーポレイテッドＥｐｉｔｒａｃｋｅｒ， Ｉｎｃ． | 加齢及び長期性の質に関連する状態の診断及び治療のための組成物及び方法 |
| EP3908374A4 (en) | 2019-01-09 | 2022-12-28 | Epitracker, Inc. | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES |
| JP7404382B2 (ja) | 2019-03-04 | 2023-12-25 | エピトラッカー インコーポレイテッド | 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用 |
| US12370166B2 (en) | 2021-11-03 | 2025-07-29 | Epitracker, Inc. | Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity |
| US12226385B2 (en) | 2021-11-12 | 2025-02-18 | Celagenex Research (India) Private Ltd. | Synergistic composition for activating intracellular secondary messenger(cAMP) pathway |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI832053A7 (fi) | 1982-06-10 | 1983-12-11 | Syntex Inc | LHRH-antagonistina käyttökelpoinen LHRH:n nonapeptidi- ja dekapeptidianalogit sekä niiden valmistusmenetevalmistusmenetelmä. |
| US4530920A (en) | 1983-11-07 | 1985-07-23 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist |
| US4659693A (en) * | 1984-04-30 | 1987-04-21 | Syntex (U.S.A.) Inc. | N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides |
| US4686283A (en) * | 1985-04-16 | 1987-08-11 | Syntex (U.S.A.) Inc. | Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis |
| IT1201511B (it) * | 1985-12-23 | 1989-02-02 | Italfarmaco Spa | Derivati citoprotettivi in patologie a base ischemica,loro preparazione e composizioni che li cntengono |
| US5352796A (en) * | 1989-10-30 | 1994-10-04 | The Salk Institute For Biological Studies | Amino acids useful in making GnRH analogs |
| US5318992A (en) * | 1990-02-26 | 1994-06-07 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of nitric oxide biosynthesis |
| MX9100717A (es) | 1990-08-24 | 1992-04-01 | Syntex Inc | Antagonistas de la bradiquinina |
| US5554638A (en) * | 1993-05-24 | 1996-09-10 | Duke University | Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders |
| US5859295A (en) * | 1994-12-05 | 1999-01-12 | University Of Kentucky Research Foundation | Canavanine analogs and their use as chemotherapeutic agents |
| GB9504350D0 (en) * | 1995-03-04 | 1995-04-26 | Sod Conseils Rech Applic | Arginine derivatives |
| BR9813554A (pt) | 1997-12-12 | 2001-07-24 | Fuji Yakuhin Kogyo Kk | Composto, uso do mesmo, processo para produzi-lo, composição farmacêutica ou veterinária, e, inibidor de metaloproteinase |
| ATE355308T1 (de) | 1998-07-16 | 2006-03-15 | Univation Tech Llc | Lewis-säure cokatalysatoren auf aluminium-basis für die olefinpolymerisation |
| HUP0202647A3 (en) | 1999-01-02 | 2003-12-29 | Aventis Pharma Gmbh | Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them |
| EP1022268A1 (en) | 1999-01-02 | 2000-07-26 | Aventis Pharma Deutschland GmbH | Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them |
| US6489308B1 (en) | 1999-03-05 | 2002-12-03 | Trustees Of University Of Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of nitric-oxide-induced clinical conditions |
| FR2794974B1 (fr) * | 1999-06-16 | 2001-08-17 | Exsymol Sa | Composition cosmetique pour l'amincissement a base de l-arginine, d'un analogue de l-arginine ou d'un de leurs derives, applicable par voie topique |
| JP2002241308A (ja) | 2001-02-21 | 2002-08-28 | Ikeda Mohandou:Kk | 皮膚そう痒症治療薬 |
| GB0211295D0 (en) | 2002-05-16 | 2002-06-26 | Univ London | Treatment of pain |
| CA2587444C (en) | 2004-11-12 | 2013-09-10 | Ucl Business Plc | Guanidine derivatives as inhibitors of ddah |
-
2005
- 2005-11-11 CA CA2587444A patent/CA2587444C/en not_active Expired - Lifetime
- 2005-11-11 EP EP05803552.8A patent/EP1828109B1/en not_active Expired - Lifetime
- 2005-11-11 JP JP2007540716A patent/JP5274838B2/ja not_active Expired - Lifetime
- 2005-11-11 WO PCT/GB2005/004361 patent/WO2006051314A2/en not_active Ceased
- 2005-11-11 AU AU2005303610A patent/AU2005303610B2/en not_active Ceased
- 2005-11-11 US US11/719,208 patent/US8063104B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5576485B2 (ja) | 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール | |
| JP2014503574A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| JP2018522866A5 (enExample) | ||
| EA200970670A1 (ru) | Производные 3-амино-пирроло[3,4-c]пиразол-5(1h,4h,6h)-карбальдегида в качестве ингибиторов ркс | |
| RU2009123525A (ru) | ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2 | |
| JP7469522B2 (ja) | ベンゾチアゾール類誘導体及びその使用 | |
| JP2008519815A5 (enExample) | ||
| JP2015522650A5 (enExample) | ||
| JP2009535307A5 (enExample) | ||
| JP2014532716A5 (enExample) | ||
| JP2009507896A5 (enExample) | ||
| JP2012504608A5 (enExample) | ||
| JP2016507502A5 (enExample) | ||
| JP2018529690A5 (enExample) | ||
| CZ113692A3 (en) | Quinoxalines, process of their preparation and their use | |
| JP2016540803A5 (enExample) | ||
| JP2019513830A (ja) | 抗ｂ型肝炎ウイルスのピラゾール−オキサゾリジノン系化合物 | |
| JP2017137323A (ja) | 新規抗がん剤 | |
| EP3472133B1 (en) | Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins | |
| JP2008500378A5 (enExample) | ||
| ES2715394T3 (es) | Nuevo antifúngico derivado de oxodihidropiridinacarbohidrazida | |
| AU2011271480B2 (en) | Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity | |
| JP2006500372A5 (enExample) | ||
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 |